Both ACEI and AT1 receptor blockers significantly attenuated the expression of VEGF, indicating that RRAS is playing a key role in the vascular proliferation pathway and could be a potential modality for the treatment of ROP. Here, AGTR1 is linked to retinopathy of prematurity.